psoriasis

Promising results for risankizumab continue in phase 3 trialsPhase three trials of the selective IL-23 blocker risankizumab are replicating the promising results achieved by phase two trials for psoriasis, researchers report in London.
Psoriasis patients have a heightened risk of malignant lymphomaPatients with psoriasis are more likely than the general population to receive a diagnosis of malignant lymphoma. Why? Cutaneous T-cell lymphoma is misdiagnosed as psoriasis and can also be mistaken for atopic dermatitis due to similarities in the skin manifestation.
Caffeine can reduce inflammation in patients with eczema and psoriasisAdding caffeine to topical skin treatments would be a simple way to reduce inflammation in patients with atopic dermatitis and psoriasis, suggests a review presented at the Psoriasis: From Gene to Clinic International Congress, which took place in London this week.
Psoriasis Gene to Clinic Congress HighlightsExperts from around the world will gather in London at the Psoriasis from Gene to Clinic Congress to present and discuss the most current developments in the understanding of psoriasis and the evidence that will steer future clinical decision making. Watch here for highlights.
Latest in dermatology productsThe latest roundup of new dermatology products includes safe ultrasound treatment in the home, skincare for aging skin, and topical pain relief.
Promising new treatments for plaque psoriasisThe American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.
Does pediatric psoriasis increase cancer risk? (VIDEO)For Contemporary Pediatrics, Dr Bobby Lazzara discusses a large retrospective cohort study published in the Journal of the American Academy of Dermatology that examined whether children with pediatric psoriasis are at increased risk of cancer and discusses 2 caveats to the findings.
Guselkumab front and center at EADV Congress
Guselkumab front and center at EADV CongressIL-23 inhibitors represent one more very effective strategy for controlling psoriasis with PASI rates comparable to other biologics.
New guidelines: Screening for pediatric psoriasis comorbiditiesRecommendations emphasize early detection of risks for medical comorbidities later in life.
Psoriasis and atopic dermatitis respond to IL-17 creamNitric oxide-releasing cream that targets IL-17 moving toward clinical trials.